Compare DCOM & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCOM | PCRX |
|---|---|---|
| Founded | 1864 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1996 | 2011 |
| Metric | DCOM | PCRX |
|---|---|---|
| Price | $29.10 | $24.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $34.17 | $33.83 |
| AVG Volume (30 Days) | 265.7K | ★ 736.4K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | 0.47 |
| Revenue | $340,529,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $52.73 | $7.27 |
| Revenue Next Year | $16.33 | $10.18 |
| P/E Ratio | ★ $24.90 | $51.07 |
| Revenue Growth | ★ 8.54 | 3.14 |
| 52 Week Low | $23.25 | $16.41 |
| 52 Week High | $37.13 | $27.64 |
| Indicator | DCOM | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 57.12 |
| Support Level | $27.81 | $23.29 |
| Resistance Level | $29.06 | $24.50 |
| Average True Range (ATR) | 1.04 | 1.00 |
| MACD | 0.38 | 0.08 |
| Stochastic Oscillator | 94.66 | 67.67 |
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.